Thèse de doctorat : Università della Svizzera italiana, 2021 ; 2021BIOMED001.
Background: Dementia is a syndrome characterized by progressive cognitive impairment, psychological and behavioural symptoms, and functional deficits. It is one of the leading causes of disability worldwide; its impact and the associated costs are enormous. Consequently, dementia is a global public health priority, and so is Alzheimer’s disease (AD), the most common cause of dementia in late...
|
In: Schizophrenia Bulletin, 2017, vol. 43, no. 5, p. 1027-1035
|
In: European Archives of Psychiatry and Clinical Neuroscience, 2015, vol. 265, no. 4, p. 273-280
|
In: Psychiatric Quarterly, 2015, vol. 86, no. 2, p. 153-168
|
In: Archives of Sexual Behavior, 2015, vol. 44, no. 5, p. 1147-1163
|
In: Heliyon, 2020, vol. 6, no. 5, p. e04025
The brain's major inhibitory neurotransmitter gamma-aminobutyric acid (GABA) and the brain-derived neurotrophic factor (BDNF) play important roles in several stress- related disorders. Magnetic resonance spectroscopy (MRS) allows for non-invasive quantification of GABA concentration in the brain. We investigated the relationship between GABA concentration in the left dorsolateral prefrontal...
|
In: Bipolar Disorders, 2019, p. -
Background: Impairments in affective cognition are part of the neurocognitive profile and possible treatment targets in bipolar disorder (BD), but the findings are heterogeneous. The International Society of Bipolar Disorder (ISBD) Targeting Cognition Task Force conducted a systematic review to (i) identify the most consistent findings in affective cognition in BD, and (ii) provide...
|
In: Translational Psychiatry, 2019, vol. 9, no. 1, p. 170
There is growing evidence for GABA and glutamate–glutamine dysfunction in the pathogenesis of mood and anxiety disorders. It is important to study this pathology in the early phases of the illness in order to develop new approaches to secondary prevention. New magnetic resonance spectroscopy (MRS) measures allow determining glutamine, the principal metabolite of synaptic glutamate that is...
|
In: European Archives of Psychiatry and Clinical Neuroscience, 2014, vol. 264, no. 7, p. 557-565
|
In: Psychopharmacology, 2014, vol. 231, no. 2, p. 409-417
|